Certara Investor Day Presentation Deck
Drug approvals using biosimulation
Our customers, who use our software and technology-driven services,
have received 90% of FDA drug approvals for 7 consecutive years.*
FDA Novel Drug Approvals Received by Our Clients
2014 - 2020
Orphan designation
Oncology
Infectious disease
Neurology
Hematology
Dermatology
Cardiology
Gastroenterology
Pulmonary
Diabetes
Migraine
Psychiatry
Sleep disorders
Bone
Other
0
20
40
60
Number of Drug Approvals
80
*Excludes diagnostics
Orphan designation applies across therapeutic areas
100
120
140
maribavir
tepotinib
ponesimod
maralixibato
atogepanta
asciminib:
sotorasib
2021 Novel Drug Approvals Using
Certara Solutions
brincidofovir
casimersen
Drug
Approvals
mobocertinib
belumosudil
belzutifan
yoclosporin
illustrative examples
Industry
Adoption
20
Innovation
Regulatory
Guidances
CERTARAView entire presentation